Browse Category

NASDAQ:VOR News 9 December 2025

Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors

Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors

Vor Biopharma Inc. (NASDAQ: VOR) has exploded back onto traders’ screens. On December 9, 2025, the small-cap biotech surged roughly 31%, closing around $10.95 versus $8.36 the prior session, on volume tens of millions of shares—far above its recent daily average. StockAnalysis+1 The move followed new bullish coverage from JPMorgan, fresh clinical data around Vor’s lead drug telitacicept, and a controversial stock-option repricing that could shape the company’s governance story for years. GuruFocus+2Investing.com+2 Below is a detailed, SEO-friendly breakdown of the latest news, forecasts, and analyses around VOR stock as of December 9, 2025. Key takeaways on Vor Biopharma (VOR)

Stock Market Today

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

7 February 2026
Rio Tinto’s U.S. shares closed up 2.5% at $93.37 Friday after the company ruled out a merger with Glencore, triggering a six-month “no-bid” lockout under UK takeover rules. Both companies cited disagreements over valuation. Attention now turns to Rio’s Feb. 19 results and iron ore prices, which fell below $100 a tonne amid weak Chinese demand.
iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Go toTop